Evidence map›Paper›PMID 30499247›Full record

ArticleHepatology research : the official journal of the Japan Society of Hepatology2019

Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion.

Haruhiko Takeda, Norihiro Nishijima, Akihiro Nasu, Hideyuki Komekado, Ryuichi Kita, Toru Kimura, Masatoshi Kudo, Yukio Osaki

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology research : the official journal of the Japan Society of Hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Targeted therapy for hepatocellular carcinoma.Signal transduction and targeted therapy · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Haruhiko TakedaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto.
Norihiro NishijimaDepartment of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka.
Akihiro NasuDepartment of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka.
Hideyuki KomekadoDepartment of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka.ORCID https://orcid.org/0000-0002-9124-7791
Ryuichi KitaDepartment of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka.
Toru KimuraDepartment of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka.
Masatoshi KudoDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Yukio OsakiDepartment of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lenvatinib is a novel multikinase inhibitor that has recently shown antitumor activity against hepatocellular carcinoma (HCC) in a phase III trial. We report the case of a woman in whom lenvatinib showed long-term antitumor activity, and in whom computed tomography (CT) scans revealed a series of suggestive radiological changes on the intratumor vascularity. A 68-year-old woman with hepatitis C virus-related liver disease presented with multiple HCCs. Following previous therapy, including six sessions of transcatheter arterial chemoembolization, we introduced lenvatinib monotherapy. Lenvatinib could rapidly cause hypovascularity in the main hypervascular target lesion, and portal vein tumor thrombosis also became undetectable 11 months after the initiation of lenvatinib. These radiological changes suggested that lenvatinib could exert not only anti-angiogenic activity but also direct antitumoral effect. Of note, CT scans during lenvatinib treatment revealed the target lesion as a low-density area in the early arterial phase, whereas scans during drug interruption due to proteinuria showed that the lesion was enhanced in the arterial phase. Finally, near-complete response could be achieved as the best response. We successfully managed various adverse events including proteinuria and hypertension, and the patient was able to continue this lenvatinib therapy for more than 4 years with well-controlled general condition. We report the first case of a patient with HCC in whom lenvatinib monotherapy demonstrated long-term antitumor activity. Suggestive radiological changes reflecting intratumor vascularity as presented here should be considered in patients receiving lenvatinib for HCC.

Indexed as

hepatocellular carcinomaintratumoral vascularitylenvatinibmodified RECISTmolecular targeting therapyresponse

Identifiers

PMID30499247
PMCPMC6850300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.